Johnson & Johnson's SPECTREM Study Shows TREMFYA® (Guselkumab) Significantly Clears Low BSA Plaque Psoriasis In Special Sites; Achieves Primary And Secondary Endpoints In Phase 3b Trial

Benzinga · 10/25 12:08

Launches Clinical Image Library To Aid Decision-Making For Diverse Skin Tones